Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma

NCT04446962 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT04446962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04446962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
Lead sponsor
Institut Curie
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 30, 2020
Completion date
August 30, 2035
Enrollment
118 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system neoplasms, primary, lymphoma, large b-cell, diffuse